Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia


Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

Asciminib Continues to Best SOC TKIs as Secondary End Points of ASC4FIRST Trial are Met

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

Olverembatinib May Be Effective in Second Line for CP-CML

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

News Network

January 23, 2019

Videos

FDA Approvals of a Biosimilar and DTC Genetic Test, Breakthrough Designation in MZL, and More

January 23, 2019

Latest Conference Coverage